A preclinical evaluation reported that the breast cancer trastuzumab biosimilar Tuznue matches reference Herceptin across critical biofunctional assays and physicochemical quality attributes. The study positioned biosimilarity on multiple measured endpoints, aiming to support later clinical comparability assessment. For the biosimilar pipeline, the comparability framework is central: demonstrating alignment across assays that reflect binding, activity, and product quality is a prerequisite to advancing into efficacy and safety studies. The report suggests that Tuznue’s analytical profile is consistent with established reference characteristics. With high costs continuing to drive demand for competitive biologics, Tuznue’s reported assay-level matching adds one more candidate to the growing set of antibody biosimilar programs targeting oncology care.